Abstract: The present invention relates to an improved modified antibody, of which solubility is increased and which can be concentrated to have a high concentration and a method for manufacturing same, and to a modified antibody in which amino acids located in the framework region of the antibody are substituted, and a method for manufacturing same.

Abstract: The present disclosure relates to an antibody to inhibit function of Angiopoietin-2 (Ang-2) by binding specifically to Ang-2, and directed to an anti-Ang2 antibody, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method of preparing the same, an angiogenesis inhibitor comprising the same, a composition for treating a disease related with Angiopoietin-2 activation and/or overproduction, a composition for diagnosing a disease related with Angiopoietin-2 activation and/or overproduction, a composition for treating eye disease or a composition for preventing or treating a cancer, and a composition for combining an antibody binding to Ang2 with a drug other than the antibody binding to Ang2.

Abstract: Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.

Abstract: Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.